🔬 PubMed Lab
日本語で入力するだけで、PubMed の英語論文を検索できるリサーチアシスタントです。
卒論・研究テーマ探し、興味のある論文を効率よく見つけられます。
🎓 卒論・修論テーマを AI が提案
この 5 本の論文を俯瞰して、あなたが実際に卒論・修論で研究できるテーマを 3 つ提案します。
📖 このサイトの解説記事から (日本語で読める)
PubMed Trivia が過去に取り上げた論文を日本語で解説している記事です。
🔍 PubMed の検索結果
-
Glucagon-like peptide 1 (GLP-1).
The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, …
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
The neurobiology of overeating.
Food intake serves to maintain energy homeostasis; however, overeating can result in obesity, which is associated with serious health complications. In this review, we explore the intricate relationship between overeating, obesity, and the underlying neurobiological mechanisms. We review the homeostatic and hedonic feeding systems, highlighting the role of the hypothalamus and reward systems in co…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder.
Glucagon-like peptide-1 (GLP-1) is abundant in the circulation, and it is well-known to regulate glucose homeostasis, feeding, and body weight. GLP-1 receptor agonists are therefore approved for treating type 2 diabetes and obesity. However, more recent research has demonstrated that GLP-1 acts within the brain to modulate reward responses, thereby highlighting GLP-1 as a potential target for addi…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.
Gut-derived hormones, such as GLP-1, have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decreases in food intake and body weight. We hypothesized that food intake reduction after GLP-1 receptor activation is mediated through appetit…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.
Alcohol use disorder (AUD) remains a major public health challenge, yet effective pharmacotherapies are limited. As such, there is growing interest in repurposing medications with novel mechanisms of action. Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for type 2 diabetes, have emerged as promising candidates due to effects on intake regulation and reward processing. GLP…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
IUPHAR review - Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target.
Addiction is a chronic relapsing disease with high morbidity and mortality. Treatments for addiction include pharmacological and psychosocial interventions; however, currently available medications are limited in number and efficacy. The glucagon-like-peptide-1 (GLP-1) system is emerging as a potential novel pharmacotherapeutic target for alcohol and other substance use disorders (ASUDs). In this …
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights.
Substance use disorders (SUDs) remain a major public health challenge, with existing pharmacotherapies offering limited long-term efficacy. Traditional treatments focus on dopaminergic systems but often overlook the complex interplay between metabolic signals, neuroplasticity, and conditioned behaviors that perpetuate addiction. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally deve…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective.
Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD), are among the leading causes of disability worldwide and are frequently associated with treatment resistance, functional impairment, and high comorbidity with metabolic dysfunction. Increasing evidence implicates insulin resistance (IR) as a key pathophysiological factor linking metabolic and psychiatric illness. …
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake.
Central glucagon-like-peptide-1 (GLP-1) receptor activation reduces food intake; however, brain nuclei and mechanism(s) mediating this effect remain poorly understood. Although central nervous system GLP-1 is produced almost exclusively in the nucleus of the solitary tract in the hindbrain, GLP-1 receptors (GLP-1R) are expressed throughout the brain, including nuclei in the mesolimbic reward syste…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review.
Binge eating disorder (BED) is a prevalent eating disorder lacking adequate pharmacological interventions. This review examines the therapeutic potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs), medications approved for type 2 diabetes and obesity now being investigated for eating disorders through their modulation of metabolic and reward pathways. A narrative review was conducted …
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」